nCounter® miRNA Expression Panels
Helping Your Research
Conventional technologies for small RNA profiling like RNAseq can be costly, onerous, and require complex data analysis. In addition, they require RNA purification and multiple enzymatic steps that can be challenging for biofluid samples like serum and plasma. When developing reliable and robust miRNA signatures for different diseases, you need a robust and reliable platform that works well with multiple sample types.
nCounter miRNA Expression Panels utilize NanoString’s amplification-free technology to do expression profiling by direct quantification of individual RNA molecules. The assay detects miRNAs without the use of reverse transcription or amplification by using molecular barcodes. Therefore, it is easier and faster to validate miRNA biomarkers as compared to RNASeq or PCR-based platforms and the results are highly reproducible. With nCounter miRNA Expression Panels, you can:
- Reliably detect and quantitate the most biologically relevant human, mouse, or rat miRNAs directly from FFPE, blood, or biofluids
- Skip laborious library prep and process your samples with less than one hour of hands-on time
- Experience unparalleled reproducibility and specificity with a dynamic range of six logs
- Receive publication-ready figures within 24 hours with robust, off-the-shelf data analysis solutions
Panel Selection Tool
Find the gene expression panel for your research with easy to use panel pro
Find Your Panel
Product Information
Related Resources






Publications
NanoString Technology for Human Papillomavirus Typing.
High-throughput HPV typing assays with increased automation, faster turnaround and type-specific digital readout would facilitate studies monitoring the impact of HPV vaccination. We evaluated the NanoString nCounter((R)) platform for detection and digital readout of 48 HPV types in a single reaction.
Stepwise Reversal of Immune Dysregulation Due to STAT1 Gain-of-Function Mutation Following Ruxolitinib Bridge Therapy and Transplantation.
PURPOSE: Patients with heterozygous gain-of-function (GOF) mutations in STAT1 frequently exhibit chronic mucocutaneous candidiasis (CMC), immunodeficiency and autoimmune manifestations. Several treatment options including targeted therapies and hematopoietic stem cell transplantation (HSCT) are available for STAT1 GOF patients but modalities and outcomes are not well established.
Tissue-specific endothelial cell heterogeneity contributes to unequal inflammatory responses.
Endothelial cells (EC) coordinate vascular homeostasis and inflammation. In organ transplantation, EC are a direct alloimmune target.

Contact Us
Have questions or simply want to learn more?
Contact our helpful experts and we’ll be in touch soon.







